Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-complex protein 1 subunit delta (CCT4) is one of the eight distinct subunits that compose the eukaryotic chaperonin-containing TCP1 complex (also known as TRiC or CCT), a molecular chaperone complex essential for ATP-dependent folding of newly synthesized proteins such as actin and tubulin[1][2][5]. CCT4 helps maintain cellular proteostasis and architecture by promoting efficient protein folding, and forms part of large oligomeric double-ring structures, either as a hetero-oligomer within the CCT complex or as homo-oligomers capable of chaperone activity[1][5]. Beyond general protein quality control, CCT4 is linked to specific pathophysiological contexts including neurodegeneration and several cancer types, where altered expression or function contributes to disease mechanisms (notably, promoting tumor growth via mTOR pathway activation in glioblastoma)[1]. Targeting CCT4 pharmacologically is considered challenging due to the fundamental nature of its biological role.
Modulation of protein folding capacity Potential modulation of mTOR pathway activity via involvement in chaperoning mLST8 in glioblastoma
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-complex protein 1 subunit delta (CCT4).